Trial intelligence / Profile preview

Phase I/II [177Lu]Lu-NeoB plus capecitabine in GRPR-positive ER-positive HER2-negative metastatic breast cancer

2023-506717-21-00Phase 2Authorised

Sponsor

Novartis

Start

Apr 2024

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

14